LCZ 696 for Type 2 Diabetes
This trial will help researchers learn more about how diabetes affects heart function and whether a new treatment can prevent heart failure in people with diabetes.
- Type 2 Diabetes
- Diastolic Dysfunction
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Can older people participate in this research?
"This study is open to participants aged 18-85."
Do people exhibit negative side effects from LCZ 696?
"LCZ 696's safety is based off of preclinical data and was given a score of 2."
Which type of person is this research looking for?
"This clinical study is looking for 72 males and females, aged 18 to 85, that have type 2 diabetes mellitus. In addition to this broad inclusion criteria, participants must also meet the following specific conditions: EF > 50% without diastolic dysfunction or EF > 50% with grade 2 or more diastolic dysfunction, without prior diagnosis, or signs and symptoms, of heart failure, 60 male and female subjects >18years of age, Type 2 diabetes mellitus, On at least one oral hypoglycemic agent, or glucagon-like peptide analogue or insulin, for at least 6 months, Minimal distance of >450"
Are participants currently being recruited for this research?
"No, this particular clinical trial is not presently recruiting patients. However, according to the data hosted on clinicaltrials.gov, it was last edited on 8/18/2022. There are many other clinical trials (874 in total) that are actively looking for patients right now."
How many people are included in the experimental group for this clinical trial?
"This study has completed recruitment for participants. However, if you're looking for other research opportunities, 835 clinical trials are currently underway that focus on diabetes mellitus, type 2 and 39 studies are investigating the efficacy of LCZ 696."
Can you give us some background on other similar research projects to LCZ 696?
"There are currently 8 Phase 3 trials and 39 total studies being conducted for LCZ 696. The majority of these research sites are located in Montreal, but there are a grand total of 812 locations running clinical trials for LCZ 696."
What are LCZ 696's primary therapeutic benefits?
"Patients with uncontrolled hypertension and Ventricular Dysfunction can find relief with LCZ 696."